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In a case-control study with prevalence sampling, the authors explored the correlates for nocturia and their
population-level impact. In 2003–2004, questionnaires were mailed to 6,000 subjects (aged 18–79 years) ran-
domly identiﬁed from the Finnish Population Register (62.4% participated; 53.7% were female). Questionnaires
contained items on medical conditions, medications, lifestyle, sociodemographic and reproductive factors, urinary
symptoms, and snoring. Nocturia was deﬁned as  2 voids/night. In age-adjusted analyses, factors associated with
nocturia were entered into a multivariate model. Backward elimination was used to select variables for the ﬁnal
model, with adjustment for confounding. Although numerous correlates were identiﬁed, none affected  50% of
nocturia cases of both sexes. The factors with the greatest impact at the population level were (urinary) urgency
(attributable number/1,000 subjects (AN) ¼ 24), benign prostatic hyperplasia (AN ¼ 19), and snoring (AN ¼ 16)
for men and overweight and obesity (AN ¼ 40), urgency (AN ¼ 24), and snoring (AN ¼ 17) for women. Moreover,
correlates included prostate cancer and antidepressant use for men, coronary artery disease and diabetes
for women, and restless legs syndrome and obesity for both sexes. Although several correlates were identiﬁed,
none accounted for a substantial proportion of the population burden, highlighting the multifactorial etiology of
nocturia.
coronary artery disease; diabetes mellitus; life style; obesity; prostatic hyperplasia; prostatic neoplasms; sleep
disorders; urinary bladder, overactive
Abbreviations: BPH, benign prostatic hyperplasia; FINNO, Finnish National Nocturia and Overactive Bladder.
Nocturia (waking at night to urinate) is a common cause
of awakenings and may lead to sleep maintenance insomnia
(1–3).Nocturia can be bothersome (4) and is associated with
impaired mental and somatic health (5), impaired quality of
life (4), and even increased mortality (6).
The etiology of nocturia is inadequately understood.
Nocturia is frequently attributed to aging or childbirth in
women and to benign prostatic hyperplasia (BPH) in men.
Other related conditions include overactive bladder syn-
drome; nocturnalpolyuria; obstructivesleep apnea; awaken-
ingforotherreasonssuchasanxiety;primarysleepdisorders;
and use of diuretics, caffeine, or alcohol (7–9). Bedtime
ﬂuid intake correlates poorly with nocturia episodes (10).
Nocturia persists frequently following simple prostatec-
tomy (11). In one study, 38% of men reported  2 voids/
night 3 years after transurethral resection of the prostate
(12). Several pharmacologic approaches have yielded
limited nocturia reductions or signiﬁcant side effects (7,
13–25).
To our knowledge, no earlier study comprehensively
covered the possible associations of medical condi-
tions; medications; lifestyle; and anthropometric, repro-
ductive, and sociodemographic factors with nocturia.
We explored correlates for nocturia and assessed their
population-level impact in a large population-based
study.
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Finnish National Nocturia and Overactive Bladder
(FINNO) Study
In 2003–2004, questionnaires were mailed to 6,000 sub-
jects aged 18–79 years randomly identiﬁed from the Popu-
lation Register Centre. Age stratiﬁcation was used with
oversampling of younger age groups to ensure precise esti-
mates even in age groups experiencing lower nocturia fre-
quency (3, 26). More information on the FINNO Study
(including characterization of nonrespondents) has been
published previously (3, 26, 27).
Outcome
Nocturia cases were deﬁned as subjects reporting 2 or
more voids/night because this frequency involves clinically
signiﬁcant bother (4). All subjects without nocturia were
considered controls in unconditional logistic regression
analyses. Self-reported nocturia frequency was determined
by using a previously described algorithm (27) combining
responses to the Danish Prostatic Symptom Score (28)
and the American Urological Association Symptom Index
(29)(WebTable1;thisinformationisdescribedintheﬁrstof
4 supplementary tables, each referred to as ‘‘Web table’’ in
the text and posted on the Journal’s website (http://aje.
oupjournals.org/)).
Correlate assessment
Self-reported information on physician-diagnosed condi-
tions, prescribed medication, speciﬁc symptoms, and life-
style factors was obtained by using questions modiﬁed from
surveys conducted by the National Public Health Institute
(30). Comorbidity indicators were formulated for 36 con-
ditions deemed common or previously hypothesized as de-
terminants of lower urinary tract symptoms (Web Tables 1
and 2). Medication use was classiﬁed into 27 groups by
using the Anatomical Therapeutic Chemical Classiﬁcation
(31) (Web Tables 1 and 3). Lifestyle factors included body
mass index, smoking, and alcohol and coffee consumption
(Web Tables 1 and 4). The Danish Prostatic Symptom Score
questions were used to evaluate (urinary) urgency and stress
urinary incontinence (28) and the Basic Nordic Sleep Ques-
tionnaire to evaluate snoring (32) (Web Tables 1 and 4).
These symptoms have been speciﬁcally shown to be risk
factors for nocturia (26, 33, 34).
With the exception of the alcohol consumption question
(response rate: men, 86%; women, 76%), data on potential
correlates were highly available (men, 97%–100%; women,
95%–100%). Alcohol consumption was not associated with
nocturia.
Potential confounders
Age, sociodemographic factors (marital status, education,
employment, urbanization) (3), and female reproductive/
gynecologic factors (parity, postpartum period, menopausal
status, hormone therapy, hysterectomy, stress urinary incon-
tinence surgery) (27) were treated as potential confounders.
Data on urbanization, parity, and delivery date(s) were ob-
tained from the population register. Information on each po-
tential confounder was available for at least 99% of subjects.
Statistical analysis
Logistic regression was used for the analyses stratiﬁed by
sex, with nocturia as the outcome. All potential correlates
and confounders associated (P < 0.10) with nocturia in the
age-adjusted analyses (basic analysis population) were en-
tered into the multivariate model (Web Figure 1, also posted
on the Journal’s website (http://aje.oupjournals.org/)). In
these analyses, potential correlates and confounders num-
bered 16 and 2 for men and 18 and 6 for women, respec-
tively. Backward elimination techniques were used to select
variables for the ﬁnal model, with likelihood ratio tests used
to determine signiﬁcance (P < 0.05). Finally, cofactors that
were not actual confounders (they did not change any esti-
mate by  10%) were eliminated. Conﬁrmed confounders
were age for men, menopausal status for women, and em-
ploymentforboth sexes.The ﬁnal analysisincludedsubjects
with information on nocturia, correlates, and confounders
(WebFigure1).Forthecorrelatesidentiﬁed,age-standardized
sensitivity, positive predictive value, attributable fraction in
the exposed, population attributable fraction, and attributable
number were calculated (35).
RESULTS
Of the 6,000 subjects approached, 3,727 (62.4%) partici-
pated; 23 were unavailable, and 130 were excluded because
of pregnancy, puerperium, or urinary tract infection (Web
Figure 1). (The response rate was approximately 32% after
the ﬁrst round, 50% after the second round, and 62.4% after
the ﬁnal, third round.) Of the 3,597 subjects included, 98%
provided nocturia information (basic analysis population).
The 3,307 subjects (92%) who responded to all nocturia,
correlate, and confounder questions formed the ﬁnal analysis
population. Prevalence of nocturia was 12.5% (95% conﬁ-
dence interval: 10.7, 14.3) among men and 12.9% (95% con-
ﬁdenceinterval:11.0,14.9)amongwomen(agestandardized
to match Finland’s age structure (36)). Excluding subjects
with missing information on any correlate or confounder
(ﬁnal analysis population) did not change these estimates. For
more detail, refer to Table 1 and to Web Tables 2–4. Corre-
latesfornocturiaincluded(urinary)urgency,snoring,restless
legs syndrome, and obesity for both sexes; BPH, antidepres-
sant use, and prostate cancer for men; and overweight, di-
abetes, and coronary artery disease for women (Table 1).
At the population level (Table 2), urgency and snoring
(both sexes), BPH (men only), and overweight/obesity
(women only) accounted for the largest proportion of noc-
turia. At the individual level, the strongest correlate for both
sexes was urgency, although odds ratio differences between
correlates were mainly statistically nonsigniﬁcant (Table 1).
No correlate affected 50% or more of men with nocturia
(Figure 1): BPH, urgency, and snoring had the highest sensi-
tivity for nocturia (31%–49%). Of the women with nocturia,
71% were overweight or obese; other correlates were re-
ported by 50% or more of women with nocturia (Figure 2).
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ported nocturia, yielding positive predictive values of 74%
and 59%, respectively. Half of the men with BPH, and a mi-
nority of men with other correlates, reported nocturia
(Figure 1). Among women, no correlates were associated
with a 50% or greater probability of nocturia (Figure 2).
Generally, questionnaire mailing round did not affect cor-
relate prevalence. However, 4 exceptions emerged (age ad-
justed). First-round responders reported more nocturia and
urgency than responders in subsequent rounds (P for trend ¼
0.01 for both nocturia and urgency; sexes combined). More-
over, ﬁrst-round male responders reported more antidepres-
sant use (P for trend ¼ 0.04), and ﬁrst-round female
responders were slightly less obese than those in subsequent
rounds (P for trend ¼ 0.05). However, the odds ratio esti-
mates for these factors were similar for each round, suggest-
ing absence of systematic error.
DISCUSSION
In this large, population-based study, numerous factors
associated with nocturia were identiﬁed. However, no single
correlateaccountedformorethanhalfofthecasesofnocturia,
highlighting its multifactorial etiology. At the population
level, urgency, BPH, and snoring for men and overweight/
obesity, urgency, and snoring for women accounted for the
largest proportion of nocturia.
Our FINNO Study population is representative of Finnish
adults in terms of sociodemographic, anthropometric, and
female reproductive factors (3, 27, 37). The frequencies of
comorbidities, medications, and lifestyle factors were sim-
ilar to those in large-scale population surveys conducted by
the National Public Health Institute (38–40).
Concordant with earlier reports (26, 41–44), urinary ur-
gency was strongly associated with nocturia in both sexes,
yet only 1 in 3 with nocturia reported urgency. Among men,
Table 1. Prevalences (%) and Odds Ratios of Correlates for
Nocturia in Multivariate Analyses
a in the Population-based Finnish
National Nocturia and Overactive Bladder Study, Finland, 2003–
2004
Prevalence
b 95% CI OR 95% CI
Men
Urinary urgency 7.5 6.1, 9.0 7.39 4.46, 12.23
Prostate cancer 1.2 0.7, 1.8 5.45 1.74, 17.08
Antidepressant
use
2.5 1.7, 3.3 3.16 1.29, 7.73
Restless legs
syndrome
3.0 2.1, 4.0 2.91 1.30, 6.52
Benign prostatic
hyperplasia
7.8 6.3, 9.3 2.18 1.31, 3.65
Obesity
c 13.2 11.2, 15.1 2.07 1.17, 3.67
Snoring 35.1 31.9, 38.2 1.49 1.00, 2.22
Women
Urinary urgency 9.9 8.2, 11.6 4.92 3.15, 7.67
Coronary artery
disease
4.5 3.1, 5.8 3.13 1.48, 6.64
Restless legs
syndrome
3.6 2.5, 4.8 2.86 1.41, 5.83
Diabetes 4.7 3.4, 5.9 2.68 1.38, 5.20
Obesity
c 13.3 11.4, 15.3 2.18 1.30, 3.66
Overweight
c 32.3 29.2, 35.4 1.90 1.25, 2.88
Snoring 18.4 16.1, 20.7 1.76 1.17, 2.64
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Also adjusted for identiﬁed confounders (age and employment for
men; employment and menopausal status for women).
b Age standardization using the age structure of Finland (36).
c Normal-weight (body mass index < 25 kg/m
2) subjects were con-
sidered the reference (37).
Table 2. Fraction of Nocturia Attributable to Identiﬁed Correlates in
the Population-based Finnish National Nocturia and Overactive
Bladder Study, Finland, 2003–2004
a
Attributable
Fraction
in the
Exposed, %
b,c
Population
Attributable
Fraction, %
c,d
Attributable
No./1,000
Subjects
c,e
Men
Urinary urgency 77.2 24.0 24
Benign prostatic
hyperplasia
69.1 13.1 19
Snoring 30.3 14.4 16
Obesity
f 29.1 5.9 6
Antidepressant use 65.6 4.3 6
Restless legs
syndrome
53.1 4.7 4
Prostate cancer 65.8 3.9 3
Women
Overweight/obesity
f 51.5 35.4 40
Urinary urgency 71.0 21.3 24
Snoring 46.8 16.4 17
Diabetes 63.3 8.6 9
Restless legs
syndrome
63.4 7.4 7
Coronary artery
disease
44.9 7.4 4
a Age standardization using the age structure of Finland (36).
b Attributable fraction in the exposed refers to the proportion by
which prevalence of the condition (nocturia) among exposed persons
(with the correlate) would be reduced if the exposure (correlate) were
eliminated (35).
c Regarding formulae of attributable fractions and attributable num-
ber, it is assumed that causes other than the one under investigation
have similar effects on the exposed and unexposed groups (35).
d Population attributable fraction refers to the proportion by which
prevalenceof thecondition(nocturia)in theentirepopulationwouldbe
reduced if the exposure (correlate) were eliminated (35).
e Attributable number refers to the number of prevalentcases of the
condition (nocturia) attributable to the exposure (correlate) (35).
f Body mass index (BMI) was classiﬁed as a dichotomous variable
when calculating attributable fractions because of the dichotomous
nature of these measures. Hence, the reference groups were not
obese (BMI < 30 kg/m
2) for men and normal weight (BMI < 25 kg/m
2)
for women because overweight (BMI 25–30 kg/m
2) was associated
with nocturia in women only.
Factors Associated With Nocturia 363
Am J Epidemiol 2009;170:361–368BPH had the second highest population impact, but only
a third with nocturia reported BPH. Lower urinary tract
symptoms suggestive of benign prostatic obstruction consti-
tute a well-recognized risk factor for nocturia (45). How-
ever, the impact of BPH may be overestimated. In Japanese
studies, nocturia was the lower urinary tract symptom least
related to prostatic obstruction, and treatment to relieve ob-
struction had less of an effect on nocturia than on other
symptoms (15, 46). In a lower urinary tract symptoms/
BPH study, patients receiving doxazosin experienced very
modest reductions in nocturia, whereas ﬁnasteride had no
effect (23). In the current study, prostate cancer was associ-
ated with nocturia. More than 70% of men with prostate
cancer reported at least 2 voids/night, yet only 7% of men
with nocturia reported prostate cancer.
Concurring with earlier ﬁndings (37, 47–49), nocturia
was associated with obesity in both sexes and, among
women, also with overweight. Indeed, overweight/obesity
had the greatest population impact among women.
Snoringhadastrongpopulationimpactbecauseofitshigh
prevalence, yet the strength of association was relatively
weak (odds ratio ¼ 1.5–1.8). Snoring has been associated
with nocturia (34). The severity of obstructive sleep apnea
predicted nocturia frequency, and continuous positive air-
way pressure treatment decreased nocturia (50). In a home
sleep study, the prevalence of obstructive sleep apnea was
double among urogynecology patients with nocturia com-
paredwith thosewithout(51).Inourstudy,reportedobstruc-
tive sleep apnea was not associated with nocturia after
adjustment, which may be due to correlation with snoring
(three-quarters of subjects with obstructive sleep apnea re-
ported snoring, and snoring was 10 times more prevalent
than obstructive sleep apnea).
To our knowledge, no association has been reported be-
tween nocturia and restless legs syndrome. Increased noc-
turia among patients with restless legs syndrome may reﬂect
sleep disturbance (52). Moreover, such patients use more
medications (particularly antidepressants) than controls do
(53). Nocturia has previously been linked to (untreated) de-
pression (54, 55) and use of selective serotonin-reuptake
inhibitors (54). In our study, only for men was nocturia
associated with antidepressant use; depression itself was
not associated with nocturia.
Diabetes and coronary artery disease were associated with
nocturia in the age-adjusted analyses for both sexes but for
only women inmultivariateanalysis. Anassociation between
diabetes and nocturia has been reported sometimes (43, 47,
49, 50, 56–60), but not always (10, 42, 45). In the BACH
Survey (47), nocturia was associated with increasing body
mass index, diabetes, and cardiac disease, whereas among
Danes aged 60–80 years (49), increasing body mass index,
diabetes, urinary incontinence,andrecurrent cystitiswere as-
sociated with 2 voids/night. In both surveys (47, 49), sex was
used as a covariate, but results were not reported by gender.
Some earlier reports (47, 59, 61), but not all (42, 43, 45, 49,
58), found cardiac/coronary disease a correlate for nocturia.
Coffee or alcohol consumption (10, 33, 41, 43, 49, 62, 63)
and smoking (33, 49, 61, 63) have been shown elsewhere not
to be associated with nocturia. Our ﬁndings were the same.
Differences in our results from previous ﬁndings may be
explained by differences in study procedures and samples
(64). Several factors explored here were not assessed in
earlier studies (10, 41–43, 45–47, 49–51, 55, 56, 58, 59,
61–63). In addition, several previous studies were not pop-
ulation based (41, 43, 46, 50, 51, 59, 61). The association of
numerous factors with nocturia in age-adjusted analyses,
0
10
20
30
40
50
60
70
80
90
100
S
e
n
s
i
t
i
v
i
t
y
 
/
 
P
o
s
i
t
i
v
e
 
P
r
e
d
i
c
t
i
v
e
 
V
a
l
u
e
,
 
%
 
Sensitivity (Proportion of Nocturics With Exposure)
Positive Predictive Value (Proportion of Exposed With Nocturia)
Urinary 
Urgency
BPH Snoring Obesity AD Use RLS Prostate 
Cancer
Condition
Figure 1. Sensitivity and positive predictive value for correlates of
nocturia amongmen (in order: thecorrelate with the greatestimpact at
the population level is given ﬁrst) in the population-based Finnish
National Nocturia and Overactive Bladder Study, Finland, 2003–
2004. AD, antidepressant; BPH, benign prostatic hyperplasia; RLS,
restlesslegssyndrome.Bodymassindex (BMI) wasclassiﬁedasa di-
chotomous variable when calculating sensitivity and positive predic-
tive value because of the dichotomous nature of these measures.
Hence, the reference groups were not obese (BMI < 30 kg/m
2) for
men and normal weight (BMI < 25 kg/m
2) for women because over-
weight (BMI 25–30 kg/m
2) was associated with nocturia in women
only.
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Figure 2. Sensitivity and positive predictive value for correlates of
nocturia among women (in order: the correlate with the greatest im-
pact at the population level is given ﬁrst) in the population-based
Finnish National Nocturia and Overactive Bladder Study, Finland,
2003–2004. CAD, coronary artery disease; RLS, restless legs syn-
drome. Body mass index (BMI) was classiﬁed as a dichotomous vari-
able when calculating sensitivity and positive predictive value
because of the dichotomous nature of these measures. Hence, the
reference groups were not obese (BMI < 30 kg/m
2) for men and
normal weight (BMI < 25 kg/m
2) for women because overweight
(BMI 25–30 kg/m
2) was associated with nocturia in women only.
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propriate analysis, including controlling for confounders.
Given the multiple possible determinants (7–10, 34, 41–
43, 45–51, 54, 56–63), we assessed numerous candidates.
Because of inconsistencies in the literature, using existing
evidence to choose the potential confounders was not justi-
ﬁed. Hence, because of the exploratory nature of this anal-
ysis, we used stepwise methods for model building (65).
By our methodology, we avoided selection bias due to
treatment seeking (reﬂecting both severity and health care
service use). Our study’s strengths include 1) a representa-
tive sample of both sexes and all adult ages, 2) a high par-
ticipation rate and completeness of questionnaire responses,
3) a large number of relevant factors, 4) systematic control
for confounding, and 5) assessment of nocturia and related
symptoms with validated instruments. Furthermore, deter-
minant prevalences were largely similar by response round,
indicating absence of selection bias; any trend in the risk
estimates by response round was also lacking.
This study has some limitations. First, the validity of self-
report has not been established for all characteristics we
considered. Second, alcohol consumption reporting was in-
complete, yet nocturia prevalence did not vary by alcohol
consumption among those reporting this information. In ad-
dition, reported alcohol consumption was comparable with
the national statistics (66). Third, we had no information on
physical activity, although physical activity has not previ-
ously been related to nocturia (41). Finally, these results
from the Finnish population may not be directly generaliz-
able to other ethnicities because impact measures generally
are context speciﬁc. There may be ethnic differences in
the prevalence of nocturia. Socioeconomicstatus attenuated,
but did not entirely remove, the effect of race/ethnicity on
nocturia (67).
Nocturia has been classiﬁed as a symptom caused by 1)
nocturnal polyuria, 2) low nocturnal bladder capacity, 3) di-
minished global bladder capacity, 4) a combination of noc-
turnal polyuria and low bladder capacity, 5) global polyuria,
and/or 6) sleep disorders (7). We found several risk factors
that may well cause these pathways and, ﬁnally, nocturia.
However,thepathwaysareprobablycomplex,andtheremay
also be numerous other underlying causes for the associa-
tions, such as autonomic nervous system hyperactivity and/
or metabolic syndrome (68, 69). At the population level,
urgency, BPH, and snoring for men and overweight and obe-
sity, urgency, and snoring for women explained the largest
proportion of nocturia, whereas obesity, antidepressant use,
and prostate cancer in men; diabetes and coronary artery
disease in women; and restless legs syndrome in both sexes
had less of an impact. Even though numerous correlates for
nocturia were identiﬁed, none was associated with nocturia
in more than half of the affected subjects of both sexes,
highlighting the multifactorial etiology.
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